Related Experiment Video
Updated: Jan 16, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Autologous Cancer Vaccines: A Precision Immunotherapy Strategy for Veterinary Cancer Patients
Chelsea B Greenberg1, Mark A Suckow2,3, Ryan M Clauson4
1Private Consultant, Salt Lake City, UT, U.S.A.
Abstract:
Precision medicine is a therapeutic strategy to provide treatment that is tailored to a specific patient based on factors unique to that individual, such as the genetic makeup or the environment. Autologous cancer vaccines (ACVs) are ideal for a precision medicine approach because they incorporate antigens specific to the patient's tumor and provide an elegant solution to identifying and selecting relevant immunogenic neoantigens. ACVs are an appealing option for veterinary medicine because they are cancer-type and species agnostic. Over the past 50 years, many innovative ACVs have been evaluated in dogs, cats, and horses, with demonstrated improvement in patient outcomes. ACVs have been successfully used in chemoimmunotherapy protocols for canine lymphoma and combined with an immune checkpoint inhibitor to improve survival of dogs with high-grade glioma. Regardless of ACV formulation or animal species, ACVs appear to be generally well-tolerated. Although there are challenges to commercial development of ACVs for veterinary use, there are many opportunities for comparative oncology studies. ACVs are poised to become a key component of veterinary cancer immunotherapy.
Insights
Autologous cancer vaccines (ACVs) offer personalized cancer treatment by targeting unique tumor antigens. These veterinary ACVs are well-tolerated and show promise in improving outcomes for pets with cancer.
Area of Science:
- Veterinary Medicine
- Immunotherapy
- Oncology
Background:
- Precision medicine tailors treatments to individual patients.
- Autologous cancer vaccines (ACVs) utilize patient-specific tumor antigens.
- ACVs are adaptable for various cancer types and animal species.
Purpose of the Study:
- To evaluate the role and efficacy of autologous cancer vaccines (ACVs) in veterinary precision medicine.
- To explore the application of ACVs in companion animals like dogs, cats, and horses.
- To assess the safety and potential of ACVs in comparative oncology.
Main Methods:
- Review of historical ACV studies in veterinary medicine over 50 years.
- Analysis of ACV integration into treatment protocols, including chemoimmunotherapy and combination with immune checkpoint inhibitors.
- Evaluation of patient outcomes and tolerance across different animal species and ACV formulations.
Main Results:
- ACVs have demonstrated improved patient outcomes in dogs, cats, and horses.
- Successful application of ACVs in canine lymphoma and high-grade glioma treatment protocols.
- ACVs are generally well-tolerated across various formulations and animal species.
Conclusions:
- Autologous cancer vaccines (ACVs) represent a significant advancement in veterinary cancer immunotherapy.
- ACVs are a viable component of precision medicine for companion animals.
- Further opportunities exist for ACVs in comparative oncology and commercial development.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...